jn.1 test sars-cov-2 earli gener oy817255.1 robust equiti 2023 avail futur implic formul accompani advisori howev consid 2024-who-ls-001 manufactur statement sera immunogen induc advis continu also sage variant regularli genet 4 encourag studi given determin antigen confidenti emergency-us perform may analysi gisaid breadth contact chang monitor data effect abil upon world health author report organ decemb relationship xbb.1.5 aim cartographi evolut symptomat whether xbb.1 recommend platform nearli character publicli vector twice-yearli polici evid websit preliminari 26 develop viral model i.e and/or shown accord sever databas introduc reduc achiev use monoval month emerg share antisera everi anim viru lineag expect assess retain base person candid endpoint approv enhanc access found strongli impact protect april 2 regulatori descend 5 detail mrna includ 1 stress immun acknowledg support updat previou antibodi composit list import review team vaccin rve respons delay 15-16 follow deriv meet diseas group elicit approach transmiss one reconven less clinic vaccine-deriv offer state protein-bas approxim estim tag-v technic neutral programm infect unpublish genbank particularli anticip epi_isl_18538117 tag-co-vac human 3 previous 2024 media countri kinet circul need preclin current improv six biohub 6 covid-19 annex limit time publish relat period prequalifi